Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Shapiro, Geoffrey
Item TypeName
Academic Article p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.
Academic Article Cyclin-dependent kinase pathways as targets for cancer treatment.
Academic Article A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Academic Article AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Academic Article The physiology of p16(INK4A)-mediated G1 proliferative arrest.
Academic Article Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flavopiridol: Modualtion of cdk targets in clinical samples [abstract]
Academic Article Bioluminescent imaging of Cdk2 inhibition in vivo.
Academic Article Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Academic Article Anticancer drug targets: cell cycle and checkpoint control.
Academic Article Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.
Academic Article A novel p16INK4A transcript.
Academic Article Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Academic Article Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flaopiridol: Modulation of cdk targets in clinical samples [abstract]
Academic Article p16INK4A as a human tumor suppressor.
Academic Article Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Academic Article Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
Academic Article Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Academic Article Multiple mechanisms of Mcl-1 depletion by the cyclin-dependent kinase inhibitor flavopiridol in mantle cell lymphoma cell lines [abstract]
Academic Article Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Academic Article A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Academic Article The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
Academic Article Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Concept Cyclin-Dependent Kinase 2
Concept Cyclin-Dependent Kinase Inhibitor p21
Concept Cyclin-Dependent Kinase 6
Concept Cyclin-Dependent Kinase Inhibitor p16
Concept Cyclin-Dependent Kinase 9
Concept Cyclin-Dependent Kinase Inhibitor p27
Concept Cyclin-Dependent Kinase 4
Concept Cyclin-Dependent Kinase Inhibitor p18
Academic Article Cyclin-dependent kinase 4/6 inhibition in cancer therapy.
Academic Article Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Academic Article Targeting CDK4 and CDK6: From Discovery to Therapy.
Academic Article Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Academic Article Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Grant Cyclin-Dependent Kinase Inhibition During S Phase
Academic Article A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies.
Academic Article The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Academic Article CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Academic Article Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.
Academic Article MicroRNA-Mediated Suppression of the TGF-ß Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.
Search Criteria
  • Cyclin Dependent Kinase 3
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.